Wells Fargo & Company Otonomy, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.25 - $2.24 $4 - $38	-17 Reduced 1.35%	1,242 $0
Q2 2022 Aug 12, 2022	BUY	$1.72 - $2.51 $51 - $75	30 Added 2.44%	1,259 $3,000
Q1 2022 May 16, 2022	BUY	$1.72 - $2.47 $1 - $2	1 Added 0.08%	1,229 $3,000
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.31 $1 - $2	1 Added 0.08%	1,228 $3,000
Q3 2021 Nov 15, 2021	SELL	$1.22 - $2.2 $533 - $961	-437 Reduced 26.26%	1,227 $3,000
Q2 2021 Aug 16, 2021	BUY	$2.06 - $2.67 $105 - $136	51 Added 3.16%	1,664 $4,000
Q1 2021 May 13, 2021	SELL	$2.49 - $6.23 $120,125 - $300,553	-48,243 Reduced 96.76%	1,613 $4,000
Q4 2020 Feb 09, 2021	BUY	$3.48 - $6.47 $54,030 - $100,453	15,526 Added 45.23%	49,856 $322,000
Q3 2020 Nov 05, 2020	SELL	$3.16 - $4.36 $16,153 - $22,288	-5,112 Reduced 12.96%	34,330 $139,000
Q2 2020 Aug 13, 2020	BUY	$1.87 - $3.84 $72,701 - $149,291	38,878 Added 6893.26%	39,442 $142,000
Q1 2020 May 14, 2020	BUY	$1.58 - $4.06 $891 - $2,289	564 New	564 $1,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.